Open Access

Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line

  • Authors:
    • Satoru Kitazono
    • Yuichi Takiguchi
    • Hironori Ashinuma
    • Miyako Saito-Kitazono
    • Atsushi Kitamura
    • Tetsuhiro Chiba
    • Emiko Sakaida
    • Ikuo Sekine
    • Yuji Tada
    • Katsushi Kurosu
    • Seiichiro Sakao
    • Nobuhiro Tanabe
    • Atsushi Iwama
    • Osamu Yokosuka
    • Koichiro Tatsumi
  • View Affiliations

  • Published online on: October 3, 2013     https://doi.org/10.3892/ijo.2013.2120
  • Pages: 1846-1854
  • Copyright: © Kitazono et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer chemotherapy, including molecular targeted therapy, has major limitations because it does not kill all the cancer cells; the residual cells survive until they acquire chemoresistance. In the present study, the combined effects of metformin and gefitinib were examined in vivo in a mouse xenograft model, inoculated with a human lung adenocarcinoma cell line that possesses an activating epidermal growth factor receptor mutation. The mechanism of the interaction was further elucidated in vitro. Metformin did not suppress the growth of already established tumors, nor did metformin augment tumor shrinkage by gefitinib. However, metformin significantly suppressed the regrowth of the tumor after effective treatment with gefitinib, suggesting the specific effect of metformin on the residual cells. Cytotoxicity of metformin was characterized by the absence of apoptosis induction and unremarkable cell cycle shift in vitro. The residual cell population after treatment with gefitinib was characterized by enriched cells with high expression of CD133 and CD24. Metformin was still effective on this specific cell population. Targeting residual cells after chemotherapy may represent an effective novel strategy for the treatment of cancer. Elucidating the mechanism of metformin cytotoxicity provides insights into future development of anticancer therapeutics.
View Figures
View References

Related Articles

Journal Cover

December 2013
Volume 43 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kitazono, S., Takiguchi, Y., Ashinuma, H., Saito-Kitazono, M., Kitamura, A., Chiba, T. ... Tatsumi, K. (2013). Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. International Journal of Oncology, 43, 1846-1854. https://doi.org/10.3892/ijo.2013.2120
MLA
Kitazono, S., Takiguchi, Y., Ashinuma, H., Saito-Kitazono, M., Kitamura, A., Chiba, T., Sakaida, E., Sekine, I., Tada, Y., Kurosu, K., Sakao, S., Tanabe, N., Iwama, A., Yokosuka, O., Tatsumi, K."Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line". International Journal of Oncology 43.6 (2013): 1846-1854.
Chicago
Kitazono, S., Takiguchi, Y., Ashinuma, H., Saito-Kitazono, M., Kitamura, A., Chiba, T., Sakaida, E., Sekine, I., Tada, Y., Kurosu, K., Sakao, S., Tanabe, N., Iwama, A., Yokosuka, O., Tatsumi, K."Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line". International Journal of Oncology 43, no. 6 (2013): 1846-1854. https://doi.org/10.3892/ijo.2013.2120